To date, in human medicine, AR-targeted drugs have been approved for the treatment of prostate cancer, and different AR inhibitors are being investigated for the treatment of HBC, specifically for the LAR subtype of triple-negative breast cancer (115). This evidence concerns the gene AR and prostate cancer.